证券代码：835892 证券简称：中科美菱 公告编号：2024-019 中科美菱低温科技股份有限公司 董事会关于独立董事独立性自查情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 根据中国证券监督管理委员会《上市公司独立董事管理办法》《北京证券交 易所股票上市规则（试行）》等要求，中科美菱低温科技股份有限公司（以下简 称"公司"）董事会就公司在任独立董事王虹女士、竺长安先生、向东先生的独 立性情况进行评估并出具如下专项意见： 经核查公司独立董事王虹女士、竺长安先生、向东先生的任职经历以及签署 的相关自查文件，确认上述人员未在公司担任除独立董事以外的任何职务，也未 在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或 其他可能妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的情况， 符合《上市公司独立董事管理办法》《北京证券交易所上市公司持续监管指引第 1 号——独立董事（2023 年修订）》中对独立董事独立性的相关要求。 中科美菱低温科技股份有限公司 董事会 202 ...

Financial Performance - In 2023, Zhongke Meiling reported operating revenue of ¥302,785,719.33, a decrease of 25.51% compared to ¥406,489,091.83 in 2022[28]. - The net profit attributable to shareholders was ¥16,126,507.82, down 69.33% from ¥52,586,940.63 in the previous year[28]. - The gross profit margin improved slightly to 38.32% in 2023 from 38.17% in 2022[28]. - The basic earnings per share decreased by 75.72% to ¥0.1667 from ¥0.6867 in 2022[28]. - The weighted average return on net assets attributable to shareholders dropped to 2.69% from 17.54% in 2022[28]. - The net profit after deducting non-recurring gains and losses was ¥3,486,531.14, a decline of 91.09% from ¥39,149,709.74 in the previous year[28]. - Total assets decreased by 9.21% from 807,126,097.66 to 732,823,882.42[29]. - Total liabilities decreased by 36.25% from 205,972,761.11 to 131,303,910.06[29]. - Cash flow from operating activities improved by 74.46%, from -38,010,376.20 to -9,706,149.56[29]. - The current ratio increased by 43.35% from 3.41 to 4.89[29]. - The interest coverage ratio decreased significantly by 88.95% from 117.98 to 38.02[29]. - The company achieved a net profit of 16,126,507.82, with a basic earnings per share of 0.1667[32]. - The company reported a significant increase in investment income, rising 216.92% to 4,869,782.42 CNY from 1,536,604.68 CNY in 2022[54]. - The company’s main business revenue decreased by 25.49% year-on-year to ¥298,620,046.22, primarily due to a slowdown in large-scale procurement of low-temperature storage equipment[58]. - Net profit decreased by 69.33% year-on-year, driven by a decline in operating income, increased R&D expenses, and reduced government subsidies[56]. - The revenue from low-temperature storage equipment fell by 30.60% year-on-year, mainly due to insufficient industry demand and a weak market outlook[62]. Product Development and Innovation - The company launched a new brand, MEGSTEMAN, along with four new product series in December 2023, marking a significant milestone in the life sciences sector[6]. - The company launched the third-generation medical refrigeration box and the world's first -180℃ compression refrigeration ultra-low temperature biological storage device, filling a market gap[43]. - The company is focusing on the life sciences sector and accelerating the development and launch of strategic new products such as biological safety cabinets and liquid nitrogen biological containers[43]. - The company is developing a dual-system refrigeration technology to achieve higher energy efficiency and replace liquid nitrogen backup, addressing overseas market demands for -40℃ to -80℃ products[88]. - The company aims to optimize the performance of its existing ultra-low temperature products through the development of a three-stage throttling technology, enhancing system stability and reliability[88]. - The company is advancing a project focused on low-temperature thermal conductive materials for medical refrigeration, which is expected to significantly improve product insulation and operational efficiency[89]. - The company is working on solar-powered refrigeration technology that operates independently of the power grid, targeting remote areas and expanding market opportunities[89]. - The company is enhancing its medical refrigeration products with IoT technology, aiming to improve management and monitoring capabilities, thus increasing market competitiveness[89]. - The company is collaborating with Anhui Blatter Intelligent Technology on the development and industrialization of an ultra-low temperature intelligent biological sample library[90]. - The company is also partnering with Shanghai Qiyao Power Technology on the ultra-low temperature Stirling cooler project, indicating a focus on innovative cooling solutions[90]. - The company is in the prototype stage for a new laboratory centrifuge product line, aimed at meeting strong market demand for centrifuge equipment[89]. - The company is developing a smart biological sample storage system that enhances safety and efficiency in sample management, addressing market needs for high-quality storage solutions[89]. Research and Development - Research and development expenses increased by 17.91% to 33,335,275.72 CNY, reflecting the company's commitment to innovation[54]. - R&D expenditure for 2023 amounted to ¥33,335,275.72, representing 11.01% of operating revenue, an increase from 6.96% in the previous year[85]. - The company holds a total of 363 patents, up from 306 in the previous period, including 18 invention patents compared to 12 previously[86]. - The company has implemented a tax deduction policy for R&D expenses, allowing for a 100% pre-tax deduction for actual R&D costs incurred[84]. Market Strategy and Operations - The company is focusing on internationalization of medical products in collaboration with SGS[7]. - The domestic marketing strategy emphasizes user-centric channel system construction and service marketing upgrades, addressing logistical challenges[45]. - The medical device industry is expected to continue growing due to increasing healthcare spending and the expansion of the biopharmaceutical sector[46]. - National policies are providing significant support for the medical device industry, encouraging innovation and domestic equipment replacement[48]. - The company is transitioning from low-margin C-end business to focus on higher-margin products, impacting overall business performance[42]. - The company aims to enhance customer satisfaction through improved after-sales service and localized support[45]. - The company plans to optimize its strategic layout by focusing on high-quality resources and gradually exiting low-margin, low-price C-end businesses[63]. - The company is committed to establishing a comprehensive deep-cooling storage technology system to support the growing demand for ultra-low temperature storage solutions[89]. Corporate Governance and Compliance - The company has established a governance structure to prevent conflicts of interest from major shareholders[110]. - The company has passed the re-certification as a high-tech enterprise, maintaining a 15% corporate income tax rate for three years[110]. - The company has implemented measures to reduce related party transactions to mitigate operational risks[110]. - The company’s governance practices align with the requirements of the Company Law and other relevant regulations, with no violations reported[184]. - The company has established a robust internal control system, ensuring compliance and effective management of operations, with no significant internal control deficiencies reported during the period[195]. - The company emphasizes investor relations management, ensuring timely and accurate information disclosure through various channels[198]. Social Responsibility and Sustainability - The company established a scholarship at Tsinghua University to support education in life sciences, reflecting its commitment to social responsibility[97]. - The company donated an automated vaccination workstation valued at RMB 1.15 million to enhance vaccination efficiency and safety[98]. - The company upgraded its waste gas treatment technology, improving the efficiency of organic waste gas collection and reducing emissions[99]. - The company has implemented a paperless office initiative to reduce paper usage and promote environmental sustainability[99]. - Energy conservation and environmental protection are becoming critical evaluation criteria for products, aligning with national goals for carbon neutrality and sustainability[103]. Financial Management - The company raised a total of ¥386,923,744 through public offerings, with ¥59,578,496.42 utilized during the reporting period[149]. - The company distributed cash dividends of ¥1.8 per 10 shares, totaling ¥17,411,568.12 to shareholders[153]. - The company has short-term loans totaling ¥10,000,000 with an interest rate of 3.30%[152]. - The company has not changed the purpose of the raised funds during the reporting period, adhering to regulatory requirements[150]. - The company has committed to purchasing its own shares using the performance incentive funds granted to executives[159]. Employee and Shareholder Relations - The total number of employees decreased from 746 to 614, a reduction of 132 employees, primarily in production and sales roles[166][167]. - The company’s total shareholding by executives increased to 3,177,993 shares, representing 3.2855% of total shares[160]. - The company has implemented a competitive salary policy, including basic, seniority, and performance-based salaries, along with additional benefits such as commercial insurance and health check-ups[168]. - The company’s independent directors receive an annual allowance of RMB 100,000, as approved by the shareholders' meeting[165]. - The company has established a harmonious labor relationship by protecting employee rights and interests through various management systems[96].

证券代码：835892 证券简称：中科美菱 公告编号：2024-023 中科美菱低温科技股份有限公司 董事会审计委员会 2023 年度履职情况报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 公司董事会审计委员会根据《公司法》《证券法》《上市公司独立董事管理 办法》《北京证券交易所上市公司持续监管指引第 1 号——独立董事》等法律法 规及规则指引要求，在 2023 年度内认真履职。现将本年度履职情况汇报如下： 一、基本情况 公司董事会审计委员会由 3 名不在公司担任高级管理人员的独立董事组 成，分别为王虹女士、竺长安先生、向东先生，其中王虹女士为会计专业人 事，担任公司审计委员会主任委员（召集人）。 二、会议召开情况 2023 年度，公司董事会审计委员会共召开 4 次会议，具体情况如下： | 会议名称 | | 召开时间 | | | | 审议事项 | 表决结果 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 第三届董事会审计 ...

Financial Performance - The company's net profit for 2023 is expected to be approximately ¥1,612.65 million, a decrease of 69.33% compared to ¥5,258.69 million in the previous year[3]. - The decline in net profit is primarily attributed to a decrease in operating revenue, increased R&D expenses, and a significant reduction in government subsidies received[4]. - Government subsidies received in 2023 have decreased significantly compared to 2022, impacting overall profitability[5]. Strategic Initiatives - The company has optimized its strategic layout by exiting low-margin, low-price C-end businesses, leading to a more focused resource allocation[4]. - The company has increased its R&D investment, achieving significant breakthroughs in new technologies such as efficient refrigeration and ultra-low temperature storage, enhancing product stability and reliability[5]. - The company is advancing automation technology, biosafety, liquid nitrogen storage, and centrifugal technology as part of its new product and technology development strategy[5]. Investment Caution - The performance forecast is based on preliminary financial data and has not been audited by an accounting firm, thus investors are advised to be cautious regarding investment risks[6].

Financial Performance - The company's operating revenue for 2023 was ¥302,800,718.15, a decrease of 25.51% compared to the previous year[3] - Net profit attributable to shareholders was ¥16,126,507.82, down 69.33% year-on-year[4] - Net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,557,755.37, a decline of 90.91% compared to the previous year[4] - Basic earnings per share decreased to ¥0.1667, down 75.72% year-on-year[3] - Total assets at the end of the reporting period were ¥733,204,824.36, a decrease of 9.16% from the beginning of the period[4] - The company's equity attributable to shareholders increased by 0.06% to ¥601,519,972.36[4] Revenue Decline Factors - The decline in revenue was primarily due to a slowdown in emergency procurement in the medical and biopharmaceutical sectors and a strategic exit from low-margin C-end businesses[5] - Government subsidies received in 2023 were significantly lower than in 2022, impacting net profit[5] Research and Development - The company has made significant R&D investments, achieving breakthroughs in efficient refrigeration technology and new product development[5] - The company is focusing on diversifying its product strategy in the biomedical field through technological advancements[5]

证券代码：835892 证券简称:中科美菱 公告编号：2024-004 中科美菱低温科技股份有限公司股票交易异常波动公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、股票交易异常波动的具体情况 公司股票最近 3 个有成交的交易日（2024 年 1 月 23 日至 2024 年 1 月 25 日）以内收盘 价涨幅偏离值累计达到 41.07%，根据《北京证券交易所交易规则（试行）》的有关规定，属 于股票异常交易波动情形。 二、公司关注并核实的相关情况 1、 关注问题： （1）前期公告的事项是否取得重大进展或变化，前期披露的公告是否需要更正、补 充； 2、 核实对象： 公司控股股东、实际控制人及一致行动人，持股 5%以上股东、在任的董事、监事及高 级管理人员。 3、 核实方式： 电话询问、口头询问、微信询问等方式。 4、 核实结论： 前期公告的事项不存在需要更正、补充之处，或取得重大进展或变化；未发现可能或已 经对本公司股票交易价格产生较大影响的媒体报道或市场传闻，不涉及热点概念事项；近期 （2）是否存 ...

| | 2024-01-25 公告日期 异常期间 | | 无 | | | | --- | --- | --- | --- | --- | --- | | | 中科美菱(835892) 连续竞价 | 成交数量 | 12029478.0 | 成交金额（万 | 18168.31 | | | （股） | | | 元） | | | | 涉及事项 当日收盘价涨幅达到20%的前5只股票 | | | | | | 买/卖 | 营业部或交易单元名称 | | | 买入金额（元） | 卖出金额（元） | | 买1 | 广发证券股份有限公司上海石泉路营业部 | | | 5064165.55 | 0 | | 买2 | 东方财富证券股份有限公司拉萨东环路第二证券营业部 | | | 3103677.11 | 879002.8 | | 买3 | 方正证券股份有限公司郴州宜章环城西路证券营业部 | | | 2713497.83 | 0 | | 买4 | 东方财富证券股份有限公司拉萨东环路第一证券营业部 | | | 2678654.06 | 1502463.11 | | 买5 | 东方财富证券股份有限公司拉萨团结路第一证券营业部 | | | 24 ...

| | 2024-01-25 公告日期 异常期间 | | 无 | | | | --- | --- | --- | --- | --- | --- | | | 中科美菱(835892) 连续竞价 （股） | 成交数量 | 12029478.0 | 成交金额（万 元） | 18168.31 | | | 涉及事项 当日价格振幅达到30%的前5只股票 | | | | | | 买/卖 | 营业部或交易单元名称 | | | 买入金额（元） | 卖出金额（元） | | 买1 | 广发证券股份有限公司上海石泉路营业部 | | | 5064165.55 | 0 | | 买2 | 东方财富证券股份有限公司拉萨东环路第二证券营业部 | | | 3103677.11 | 879002.8 | | 买3 | 方正证券股份有限公司郴州宜章环城西路证券营业部 | | | 2713497.83 | 0 | | 买4 | 东方财富证券股份有限公司拉萨东环路第一证券营业部 | | | 2678654.06 | 1502463.11 | | 买5 | 东方财富证券股份有限公司拉萨团结路第一证券营业部 | | | 2495543.64 | 4574 ...

| | 公告日期 2024-01-25 异常期间 | | 2024-01-25 | | | | | --- | --- | --- | --- | --- | --- | --- | | | 中科美菱(835892) 连续竞价 （股） | 成交数量 | 20660357.0 | 成交金额（万 元） | | 29006.64 | | | 北交所股票最近3个有成交的交易日以内收盘价涨跌幅偏离值累计达到+40% 涉及事项 | | | | | | | | (-40%) | | | | | | | 买/卖 | 营业部或交易单元名称 | | | 买入金额（元） | | 卖出金额（元） | | 买1 | 广发证券股份有限公司上海石泉路营业部 | | | 5064165.55 | | 0 | | 买2 | 东方财富证券股份有限公司拉萨东环路第二证券营业部 | | | 4658653.33 | | 2811360.32 | | 买3 | 东方财富证券股份有限公司拉萨东环路第一证券营业部 | | | 4008261.02 | | 2273301.92 | | 买4 | 中天证券股份有限公司深圳中心路证券营业部 | | | 344 ...

| 日期 | 代码 | 简称 | 成交数量（股） | 成交金额（万元） | 披露原因 | | --- | --- | --- | --- | --- | --- | | 2024-01- | 873122 | 中纺标 | 18475999.0 | 73142.85 | 异常期间涨跌幅偏离值累计 | | 25 | | | | | 达到68.81% | | 2024-01- | 871753 | 天纺标 | 28343152.0 | 74196.28 | 异常期间涨跌幅偏离值累计 | | 25 | | | | | 达到44.94% | | 2024-01- | | | | | 异常期间涨跌幅偏离值累计 | | 25 | 872541 | 铁大科技 | 62780658.0 | 51807.49 | 达到41.47% | | 2024-01- | | | | | 异常期间涨跌幅偏离值累计 | | 25 | 835892 | 中科美菱 | 20660357.0 | 29006.64 | 达到41.07% | | 2024-01- | | | | | | | | 873122 | 中纺标 | 9067514 | 395 ...